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Abstract 37 
Objectives. Immunotherapy and personalized medicine therapeutics are emerging as promising approaches in 38 
the management of head and neck squamous cell carcinoma (HNSCC). In spite of that, there is yet no assay that 39 
could predict individual response to immunotherapy.  40 
Methods. We manufactured an in vitro 3D microfluidic chip to test the efficacy of immunotherapy. The assay 41 
was first tested using a tongue cancer cell line (HSC-3) embedded in a human tumour-derived matrix 42 
“Myogel/fibrin” and immune cells from three healthy donors. Next, the chips were used with freshly isolated 43 
cancer cells, patients´ serum and immune cells. Chips were loaded with different immune checkpoint 44 
inhibitors, PD-L1 antibody and IDO 1 inhibitor. Migration of immune cells towards cancer cells and the cancer 45 
cell proliferation rate were evaluated. 46 
Results. Immune cell migration towards HSC-3 cells was cancer cell density dependent. IDO 1 inhibitor induced 47 
immune cells to migrate towards cancer cells both in HSC-3 and in two HNSCC patient samples. Efficacy of PD-48 
L1 antibody and IDO 1 inhibitor was patient dependent.  49 
Conclusion. We introduced the first humanized in vitro microfluidic chip assay to test immunotherapeutic drugs 50 
against HNSCC patient samples. This assay could be used to predict the efficacy of immunotherapeutic drugs 51 
for individual patients.   52 
 53 
 54 
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Introduction 59 
Immunotherapy is considered as the newest treatment modality for head and neck squamous cell carcinoma 60 
(HNSCC) patients. Surgical removal of the tumour or definitive radiotherapy are the main approaches with 61 
curative intent for selected groups of patients with an early stage tumour. Patients with advanced stage 62 
disease at the time of diagnosis typically receive an individually tailored combination of surgery and 63 
(chemo)radio-, targeted-, and recently immunotherapy. With all these available treatments the five-year 64 
survival amongst HNSCC patients still is around 50% [1].  65 
After introducing immunotherapy, there was a hope that this new treatment approach could significantly 66 
enhance HNSCC patients’ survival. Pembrolizumab, a PD-1 inhibitor, is the first immunotherapy, which has 67 
received FDA approval for treating HNSCC patients and was followed by another anti-PD-1 drug, nivolumab [2-68 
59]. These agents are used as second line treatment after failure of platinum-based chemotherapy. In a phase 3 69 
clinical trial (NCT02252042) pembrolizumab gave a better objective response rate (14.6%, 95%CI 10.4 to 19.6) 70 
compared with the standard therapy (10.1%, 95%CI 6.6 to 14.5) for HNSCC patients [6]. Other 71 
immunotherapies are still investigated in ongoing clinical trials, such as durvalumab, avelumab (both are anti 72 
PD-1) and tremelimumab (anti CTLA-4) [7]. Similar to the other types of HNSCC treatments, there are currently 73 
no methods to predict the patients’ response to immunotherapy. This leads to a significant problem in terms of 74 
subjecting patients to unnecessary side effects and ineffective treatments, especially when the percentage of 75 
the responsive patients remains low (14.6% for pembrolizumab). Expression of PD-L1 with a cut-off of 1% was 76 
used as a requirement for giving the PD-1 antibody in a study by Seiwert et al. [5] in a series of 60 HNSCC 77 
patients, but unfortunately it did not guarantee treatment response.  78 
Although, personalized drug testing has been recently undergoing active investigation, the results have still not 79 
been translated into clinical practice despite that several models have been suggested for testing chemo-, 80 
radio- and targeted therapies. On the other hand, testing immunotherapy in in vitro setting seems to be more 81 
complicated, especially as a co-culture of two different cells i.e. cancer cells and immune cells with different 82 
adherent properties is needed. In vitro 2D culture has been considered as the gold standard for cancer 83 
research. However, with our recent knowledge, researchers have started to regard the 2D cell culture as being 84 
too far from the real in vivo condition. Thus, there is a clear shift in research setting towards using 3D cell 85 
cultures and many extracellular matrices (ECM) have been proposed to be used for this purpose. The majority 86 
of these matrices have either been extracted from animals (sarcoma mouse-derived Matrigel, rat tail type one 87 
collagen) or derived from synthetic material. Even though these matrices can provide a 3D structure for the 88 
cancer cells, they still have major limitations including missing of important elements present in the human 89 
tumour microenvironment. To overcome this problem, our group developed human tumour-based matrix 90 
“Myogel” from leiomyoma tissue [8]. Due to its neoplastic origin, Myogel seems to be suitable for human 91 
cancer 3D in vitro assays providing an ideal tumour environment for the cultured cancer cells [8,9].  92 
Microfluidic chip has been applied as one solution for studying the efficacy of immunotherapy by evaluating 93 
immune cell migration towards cancer cells [10-12]. The chip was developed by Businaro et al. [10] and was 94 
used for testing the effects of type I interferons on melanoma cells [11]. Matrigel was used in these assays to 95 
provide 3D environment for the cancer cells. Here, we aim to provide a fully human in vitro microfluidic chip 96 
assay to test immunotherapy for personalized medicine purposes for HNSCC patients. The cancer cells 97 
(including carcinoma and stromal cells) are isolated from patient-derived tumour tissue pieces and embedded 98 
in human tumour-based ECM “Myogel/fibrin”. Additionally, the immune cells and serum are collected from the 99 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
patient’s blood. All these elements are loaded into the microfluidic chip with or without immunomodulators to 100 
test both the immune cell migration towards cancer cells and their cytotoxic activity.     101 
        102 
Materials and methods: 103 
Cell line 104 
Human tongue SCC (HSC-3; Japan Health Sciences Foundation, Japan) cells were cultured in 75 cm2 flasks 105 
containing Dulbecco’s modified Eagle’s medium (DMEM)/F-12 (Gibco, Paisley, UK) supplied with 10% heat-106 
inactivated foetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin, 250 ng/ml fungizone and 107 
50 μg/ml ascorbic acid (all from Sigma-Aldrich, St. Louis, Mo, USA). To prepare the cell suspension for injection 108 
into the chip, cells were detached from the flask using trypsin/EDTA and suspended in complete media.  109 
Patient samples 110 
Samples were collected according to our institutional Research Ethics Board (14.03.2016 Eettmk 84) approval. 111 
Patient participation was voluntary and required informed consent. Clinical and pathological characteristics of 112 
the patients are presented in Table 1. 113 
The fresh tissue samples were obtained perioperatively and immersed in ice-cold Hanks’ Balanced Salt solution 114 
(HBSS; supplied with 100 U/ml penicillin, 100 μg/ml streptomycin and 250 ng/ml fungizone). The samples were 115 
taken from the area adjacent to the centre of the tumour to assure the the presence of the carcinoma tissue 116 
cells, including mostly carcinoma cells and some cancer associated fibroblasts. Each sample was placed in a 117 
petri dish containing ice-cold HBSS and necrotic tissues were removed using a scalpel. Vital tissue pieces were 118 
placed into a new petri dish containing HBSS and minced into small (1–2 mm) pieces with a scalpel. The tissue 119 
pieces were transferred to 15-ml falcon tube and centrifuged for 5 min at 1000 rpm (200 × g) at 4°C. The 120 
supernatant was discarded and a fresh HBSS buffer was added before another round of centrifugation. The 121 
tissue piece pellet was suspended in a 5 ml HBSS buffer containing 1 mg/ml collagenase type I from Clostridium 122 
histolyticum (Sigma-Aldrich, St. Louis, Mo, USA) and placed on a rocker platform at 37°C for two hours. The 123 
tube was centrifuged and the supernatant was discarded and replaced with a fresh HBSS buffer before another 124 
round of centrifugation. The digested sample was suspended in an HBSS buffer, filtered using a 100-μm cell 125 
strainer (Falcon™ Cell Strainer, Fisher Scientific, NH, USA) and the flow-through (single cells) was collected and 126 
centrifuged. The supernatant was discarded and the cell pellet was suspended in DMEM/F-12. 127 
Isolation of the human peripheral blood mononuclear cells (MNCs) and serum from the buffy coat of healthy 128 
donors and blood of cancer patients 129 
Human peripheral blood MNCs were isolated from a buffy coat of three healthy donors provided of by the 130 
Finnish Red Cross and blood of two HNSCC patients. A density gradient technique was followed to isolate MNCs 131 
using Ficoll–Paque PLUS (GE Healthcare, Piscataway, NJ, USA). As peripheral blood MNCs consists of both 132 
adaptive and innate immune cells (T cells, B cells, NK cells, monocytes, and dendritic cells), we will refer to 133 
them as immune cells. 134 
For serum collection, blood was allowed to clot at room temperature for 30 minutes and clot was removed by 135 
centrifugation at 2000 rpm for 10 minutes in a refrigerated centrifuge at 4C. 136 
Proliferation luminescent cell viability assay 137 
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Wells of 96-well plates with black well walls and clear bottoms (PerkinElmer, Waltham, MA, USA) were coated 138 
with 50 µl/well of 0.5 mg/ml Myogel (lab made) and Matrigel (Corning, Corning, NY, USA); control wells were 139 
left uncoated. The plate was incubated at the cell culture incubator overnight. Isolated cancer cells were 140 
seeded at the density of 1000 cells/well in 100 µl of complete medium. After 3 days, the plate was taken out 141 
from the incubator to room temperature for 15 min before starting the assay. One hundred µl of CellTiter-Glo 142 
was dispensed in each well. The plate was put on a plate shaker (Heidolph, Schwabach, Germany) for 5 min at 143 
450 rpm and then in plate spinner (Thermo Scientific, Massachusetts, USA) for 5 min at 1000 rpm. Finally, the 144 
plate was placed in the BMG Pheraster FS (BMG Labtech, Offenburg, Germany) plate reader to detect cell 145 
viability. 146 
Microfluidic chip design and fabrication process 147 
Standard soft lithography process was followed to fabricate the PDMS poly(dimethylsiloxane) microfluidic 148 
devices. The chip was designed with slight modification from Businaro et al. [10]. CAD software was used to 149 
design the microchannel patterns, which were then plotted on high resolution polymer films, consequently 150 
applied as photomasks for the photolithography steps. Figure 1 shows the microchannel layout, which was 151 
translated onto a master mould, containing two layered SU8 negative photoresist structures on silicon wafer 152 
following MicroChem Nano™ protocols.  153 
Each microfluidic structure contains a central 16 mm long 1.2 mm wide and 150 µm deep chamber for the 154 
immune cells, which is connected to the neighbouring cancer cell containing channels via 200 µm long, 10 µm 155 
deep and 12 um wide microchannels. The channels incorporating the cancer cells are 150 µm deep, 600 µm 156 
wide and linked to the immune cell containing channel along a 10 mm section from both sides.   157 
For preparing the PDMS replicas, Sylgard 184 (Dow Corning) was mixed with crosslinking agent in 10:1 ratio 158 
and casted over the master mould template. After keeping in vacuum for 45 min to eliminate air bubbles it was 159 
placed in a preheated oven and cured at 70 C for 2 hours. Upon cooling back to room temperature the PDMS 160 
replica was peeled off the template and the chips were cut out, the fluidic inlets and outlets punched through, 161 
including the larger circular vias defining the open liquid reservoirs. Then the PDMS surfaces were cleaned from 162 
dust with nitrogen gun and scotch tape. Glass microscope slides were thoroughly wiped and cleaned with 163 
ethanol and dried with nitrogen gun. After exposing the slides and the PDMS replicas to oxygen plasma in a 164 
PVA TePla 400 plasma system for 1 minute (power: 60 W, O2 flow rate: 500 ml/min) the PDMS chips were 165 
immediately placed on and bonded to the glass slide, providing a lid over the microchannels. Prior to loading 166 
the samples the chips were autoclaved at 120 C for 30 min.  167 
Microfluidic chip assay 168 
Cancer cells (cell line or freshly isolated tumour cells) were stained with Celltrace Far Red (Invitrogen, Carlsbad, 169 
CA, USA) according to the manufacturer’s instructions and suspended in Myogel/fibrin. Myogel/fibrin was 170 
prepared using the following concentrations: 2.4 mg/ml Myogel, 0.5 mg/ml fibrinogen (Merck, Darmstadt, 171 
Germany), 0.3 U/ml thrombin (Sigma-Aldrich), and 33.3 ug/ml aprotinin (Sigma-Aldrich); these reagents were 172 
diluted in DMEM/F12 media with 10% fetal bovine serum for the cell line experiment and patient serum for the 173 
patient sample experiment. Three microliters of cell suspension (containing 20 000 cells) in gel was loaded in 174 
each small channel (B). 175 
Immune cells were stained with CellTrace Violet (Invitrogen) and suspended in DMEM/F12 media supplied with 176 
10% serum, foetal bovine serum for cell line experiment and patient serum for the patient samples experiment. 177 
Immune cells were divided into 3 groups: control (with no drug), 9.6 µg/ml PDL-1 antibody (Bio X Cell, Hanover, 178 
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NH, USA) and 5 µg/ml IDO 1 inhibitor (NLG-919, Cayman Chemical, Ann Arbor, MI, USA). 150 µl of cells 179 
suspension (containing 1 million immune cells) was injected into the large channel (A). PD-L1 antibody and IDO 180 
1 inhibitor were added with the immune cells due to large volume of cells suspension added to the channel 181 
(150 µl) compared with only 3 µl for the cancer cells channel which allow adding higher volume of drug. 182 
Additionally, this setup is closer to the in vivo situation where the patients receive immunomodulator drugs 183 
through intravenous injection.  184 
Chips were incubated in the cell culture incubator for three days and imaged daily under fluorescence 185 
microscope using Leica DM6000 B/M light microscope connected to a digital camera (DFC420 and DFC365FX; 186 
Leica Microsystems, Wetzlar, Germany).  187 
Cells counting 188 
The number of immune and cancer cells were analysed using Matlab’s (Mathworks, Natick, MA, USA) built-in 189 
algorithm. The algorithm is semi-automated with manual thresholding. The algorithm detects positive cells 190 
when the intensity of their staining is substantially higher than the background [13]. Matlab’s built-in functions 191 
trace boundaries cells/objects.  192 
 193 
Tumour-associated immune cells were identified based on their size and morphology. For cancer cell detection, 194 
objects with smaller size than the average cell size were excluded from the quantification using object size 195 
threshold set manually. Cancer cell proliferation rate was measured by dividing the number of cancer cells each 196 
day by the number of cancer cells of day 1. 197 
 198 
Results 199 
Isolated cancer cells proliferate more on top of Myogel compared with Matrigel and uncoated wells 200 
Cancer cells were isolated from three HNSCC patients and seeded on top of plastic, Myogel and Matrigel to 201 
study their proliferation. For all the three patient samples, cancer cells had higher proliferation rate on top of 202 
Myogel compared with plastic or Matrigel (Figure 2). 203 
Immune cells migration towards cancer cells depends on cancer cells density  204 
Two chips were used to study the immune cells migration towards cancer cells. The first chip (Figure 3a) was 205 
loaded with immune and cancer cells (channels A and B, respectively). The second one (Figure 3b) was loaded 206 
only with immune cells, where instead of the cancer cells, a Myogel/fibrin gel was applied. In the first chip, 207 
during three days there was a continuous migration of the immune cells towards cancer cells. On the other 208 
hand, immune cells did not pass to channel B in the second chip (Figure 3a & b). 209 
To study if the migration of the immune cells towards the cancer cells is cancer cell density dependent, chips 210 
were loaded with two different cancer cells densities (20 000 and 10 000 cells). Immune cells from three 211 
healthy donors were used in this experiment. In all the 3 chips with high cancer cells density, more immune 212 
cells migrated towards the cancer cells compared with the chips, which were loaded with lower number of 213 
cancer cells (Figure 3c).     214 
IDO 1 inhibitor induces immune cells migration towards cancer cells 215 
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To study the effect of PD-L1 antibody and IDO 1 inhibitor on the immune cells migration, we first used HSC-3 216 
cell line and immune cells from three healthy donors. For all the three donors, IDO 1 inhibitor induced the 217 
immune cell migration (Figure 4). On the other hand, PD-L1 antibody did not increase immune cell migration, 218 
but instead it reduced it in two cases (Donor 1 and 3; Figure 4).  219 
Next, using patients´ cancer cells and their immune cells in the presence of the patients´ serum, we tested the 220 
effect of PD-L1 antibody and IDO 1 inhibitor on the immune cell migration. Similar to the cell line results, IDO 1 221 
inhibitor induced the immune cell migration towards cancer cells (Figure 5a & b).    222 
Patient dependent response to immunotherapy 223 
Two patient samples were used to test the effect of anti PD-L1 and IDO 1 inhibitor on tumour cell proliferation. 224 
While PD-L1 antibody was the most effective drug for the first patient, IDO 1 inhibitor gave the best, still 225 
modest, result for the second patient (Figure 5c).  226 
 227 
Discussion 228 
Immunotherapy is emerging as a novel treatment approach for several cancer types including HNSCC. In spite 229 
of its promising results, the percentage of responder patients remains very low [3, 4]. Due to the low number 230 
of responders, the majority of patients are subjected to ineffective drugs and unnecessary side effects. Until 231 
now, there is no marker, which could predict the patients’ response to these treatments. Here, we introduced 232 
a 3D in vitro microfluidic chip supplied with the patients’ cancer cells, their immune cells and serum to test the 233 
efficacy of immunotherapeutic drugs. The system is superior to the other existing methods since it provides a 234 
3D fully human tumour microenvironment to the cancer cells as they are embedded in human Myogel/fibrin 235 
matrix. We tested this system using a HSC-3 cell line and two HNSCC patient samples. Immune checkpoint 236 
inhibitors (PD-L1 antibody and IDO 1 inhibitor) gave variable cytotoxic activity between the patients. 237 
Additionally, we reported for the first time that IDO1 inhibitor induced immune cells migration towards cancer 238 
cells.   239 
Several immune checkpoints have been identified, such as PD-L1, B7-H3, IDO1 and CTL-4. While all these 240 
checkpoints contribute to cancer progression through immune system suppression, each one has a different 241 
mechanism. In this work we targeted two immune checkpoints, PD-L1 and IDO 1. PD-L1 is reported to be highly 242 
expressed on the HNSCC tumour cells [14]. This upregulation allows tumour cells to escape from the host 243 
immune system through induction of T-cell apoptosis, anergy, exhaustion and secretion of the anti-244 
inflammatory cytokines IL-10 [15]. IDO 1 is also upregulated in HNSCC and it induces T-cell apoptosis, and 245 
promotion of Treg differentiation through depletion of tryptophan and production of kynurenine [16, 17].  246 
Testing the immunotherapeutic efficacy is more complicated compared with that of chemo-, targeted- and 247 
radiotherapy due to the need of co-culturing the cancer and immune cells. Although many co-culture models 248 
are available, still co-culturing cancer and immune cells warrants improvement due to different adherent 249 
properties of these cells. The microfluidic chip which was designed first by Businaro et al. [10] provides a 250 
solution for this problem by using two chambers connected by micro-channels. The first chamber is filled with 251 
suspended immune cells and the other one is injected with cancer cells embedded in gel. In this study, we 252 
replaced the commonly used mouse sarcoma derived Matrigel with the human leiomyoma originated Myogel 253 
to provide better microenvironment to the cancer cells mimicking the in vivo tumour matrix. We have shown in 254 
previous studies that cancer cells migrate and invade faster on Myogel than on Matrigel [8, 9]. Here we showed 255 
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that the freshly isolated cancer cells from three HNSCC patients proliferated more on top of Myogel compared 256 
with plastic or Matrigel. This result indicates the importance of providing a suitable ECM for the 3D cell culture, 257 
which has both human and tumour properties. The chip is also supplied with the patient’s own serum instead 258 
of the commonly used FBS. This provides the cancer and immune cells with the similar mixture of proteins, 259 
which are in contact with them in vivo. 260 
Studying immune cell migration is a common method to investigate the cross-talk between cancer and immune 261 
cells [18]. It is also used as a parameter for studying the efficacy of immunotherapy [11, 12]. Interestingly, our 262 
results indicate that IDO 1 inhibitor, but not PD-L1 antibody, induced immune cells migration towards cancer 263 
cells. To the best of our knowledge, this is the first report showing the induction of immune cells migration by 264 
inhibiting IDO1. Such observation of IDO 1 inhibitor being able to induce immune cell infiltration towards 265 
cancer could change the tumour from cold to hot, if validated in vivo. This could, in theory, enhance the 266 
efficacy of the other immunotherapeutic drugs, such as PD-1 and PD-L1 antibodies, if given in combination with 267 
IDO 1 inhibitor. Therefore, we aim as the next step to test various combination therapies using our microfluidic 268 
chip assay.  269 
Our results demonstrated the variability of the drugs` efficacy between the two HNSCC patients. As PD-L1 270 
antibody was the most effective one in the patient No. 4, IDO 1 inhibitor was the most effective in the patient 271 
No. 5. To be noticed, since immune cell migration did not parallel the proliferation results, we consider the 272 
immune cell migration is not sufficient parameter to evaluate the response of the immunotherapeutic drugs, as 273 
suggested before [11]. Unfortunately, we do not have in vivo evidence of the effects of these immunotherapy 274 
drugs on our patients, since these drugs are not in clinical use yet.  275 
In conclusion, we describe here a novel humanized in vitro microfluidic chip assay for testing the efficacy of 276 
immunotherapeutic drugs against patient samples. This assay could give preliminary knowledge to the clinician 277 
on the efficacy of these drugs for individual patients.  278 
 279 
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 327 
Figure legends: 328 
Figure 1. Microfluidic chip design. Immune cells are loaded in Channel A and cancer cells in Channels B. 329 
Channels C are used for hydration.  330 
Figure 2. Cancer cells have higher proliferation on top of Myogel compared with plastic and Matrigel. Freshly 331 
isolated cancer cells from three HNSCC patients were cultured on top of plastic, Matrigel and Myogel for three 332 
days. Cancer cells´ proliferation was measured using luminescent cell viability assay. Results are presented as 333 
mean ± standard deviation.  334 
Figure 3. Immune cells migration towards cancer cells depends on cancer cells density. Cancer cells were 335 
labelled with cell trace far red, embedded in Myogel/fibrin and injected in channel B of the first chip (a). 336 
Immune cells were labelled with cell trace violet and loaded in channel B in the first and second chips (a and b). 337 
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Migration of the immune cells was only detected in the first chip (a). Immune cells migration was dependent 338 
on the number of the injected cancer cells (c).  339 
Figure 4. IDO 1 inhibitor induces immune cells migration towards cancer cells. Cancer (red) and immune cells 340 
(blue, from three healthy donors) were loaded in the microfluidic chips. The chips were supplied with PD-L1 341 
antibody and IDO1 inhibitor, no drugs were added to the control chips. Number of infiltrated immune cells 342 
were counted over three days. 343 
Figure 5. Migration of the patients´ immune cells and their effects on the cancer cells proliferation. Isolated 344 
cancer and immune cells (both from HNSCC patients) were labelled with cell trace far red and violet, 345 
respectively. Cells were injected in the microfluidic chips in the presence or absence of PD-L1 antibody and 346 
IDO1 inhibitor (a).  Number of the infiltrated immune cells (b) and the cancer cells proliferation rate (c) were 347 
measured over three days. 348 
 349 
 350 
 351 
 352 
 353 
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Table 1: Clinical and pathological characteristics of the HNSCC patients. 
Patient 
number 
Sex
a
 Age
b
 TNM Specimen site 
Grad
e 
1 F 73 T3N0M0 Gingiva G3 
2 F 80 T2N0M0 Buccal mucosa G2 
3 F 68 T4aN0M0 
Overlapping lesion of other and unspecified parts of 
mouth G1 
4 M 61 T2N0M0 Mobile tongue G3 
5 M 53 T3N0M0 Mobile tongue G2 
a
M=male , F=female, 
b
 Age in years 
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Highlights 
• Immunotherapy is emerging as the most promising approaches in cancer treatment  
• There is no personalized assay that can predict patient response to immunotherapy 
• We introduced fully humanized microfluidic chip to test immunotherapeutic drugs 
• The chip is loaded with isolated cancer cells, patients´ serum and immune cells 
• Several immunotherapeutic drugs can be tested for each patient simultaneously 
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